Background: It is commonly accepted that testicular function is prevalently regulated by the hypothalamic-pituitary-gonadal axis: The pulsatile secretion of GnRH by the hypothalamus induces pituitary expression of the two gonadotropins FSH and LH, which then stimulate Sertoli and Leydig cells, respectively, therefore regulating steroidogenesis and spermatogenesis. However, a growing body of evidence has recently suggested that other hormones act on the reproductive tract since the early phases of fetal development. Anti-M€ ullerian hormone and INSL3 are still largely used only for research purposes despite being increasingly recognized as markers of Sertoli and Leydig cells function, respectively. Objectives: Provide an up-to-date review of the role of anti-M€ ullerian hormone and INSL3 in human pathophysiology according to current evidence. Materials and Methods: A thorough literature review was performed on PubMed, OVID MEDLINE/EMBASE and Google Scholar for papers concerning anti-M€ ullerian hormone and INSL3 in human males. Results: INSL3 is not acutely regulated by the hypothalamic-pituitary axis but is constitutively secreted by Leydig cells, therefore representing a valid marker for their number and status. Anti-M€ ullerian hormone expression, on the other hand, is downregulated by androgens, therefore occurring mostly at the early stages of testicular differentiation and before the onset of puberty. Several conditions affecting testicular development, such as male hypogonadotropic hypogonadism, and their treatment have been associated to specific pattern of INSL3 and anti-M€ ullerian hormone expression, proving a role for both hormones in the diagnostic and therapeutic management. Recent reports suggest a role for both anti-M€ ullerian hormone and INSL3 in extra gonadal physiology, such as cardiovascular and bone health. Conclusion: Anti-M€ ullerian hormone and INSL3 are markers of Sertoli and Leydig cells maturation, respectively, usually involved in the pathogenesis of disorders of sexual differentiation. However, their role in testicular pathology has only been hinted at in the last decades. Recent evidence supports an involvement of both anti-M€ ullerian hormone and INSL3 in extragonadal pathophysiology as well.
INTRODUCTION
Testicular functions include spermatogenesis and hormone production-both largely dependent on the integrity of the hypothalamic-pituitary-gonadal (HPG) function and of the testis itself. It is textbook knowledge that GnRH is secreted by hypothalamic GnRH-secreting neurons into the hypophyseal portal circulation; from here, GnRH reaches the anterior pituitary, where it induces release of the two gonadotropins LH and FSH by binding to its receptor on the surface of gonadotrope cells (Stamatiades & Kaiser, 2018) . Secretion of GnRH is pulsatile: the pituitary response is affected by frequency and amplitude of each pulse, with low and high pulse frequencies, respectively, stimulating FSH and LH release (Stamatiades & Kaiser, 2018) , and pulsatility changes dramatically during life, decreasing in frequency and amplitude (Bhasin et al., 2000) . In males, FSH and LH act on specific receptors predominantly expressed in the testis: receptors for FSH are mostly expressed by Sertoli cells, whereas Leydig cells express LH receptors. The binding of LH to its receptor on Leydig cells induces testosterone synthesis by increased activity of the desmolase enzyme (Dufau et al., 1984) ; similarly, FSH binds to its receptor on Sertoli cells, activating several pathways ultimately needed for supporting spermatogenesis (Simoni et al., 1997; Walker & Cheng, 2005; Lucas et al., 2014 ). An intra testicular paracrine role has been clearly identified for testosterone, suggesting that its binding to the androgen receptor is the key stimulus for successful spermatogenesis (Huhtaniemi, 2015) . On the contrary, the role of FSH has been somewhat questioned in the last few years: studies in men with polymorphisms in the genes for either the b chain of the FSH molecule (FSHB) or the FSH receptor (FSHR) have shown that clinical phenotypes may differ, ranging from azoospermia (Huhtaniemi, 2003) to normal sperm counts (T€ uttelmann et al., 2012) . These polymorphisms could negatively influence serum FSH levels (FSHB) or the FSH receptor affinity (FSHR), therefore possibly impairing reproductive health (T€ uttelmann et al., 2012) ; however, clinical manifestations largely depend on the combination of the two alleles (T€ uttelmann et al., 2012) . A different approach to the hormonal regulation of spermatogenesis seems to suggest that in mammals, as a result of evolutionary changes, FSH is acting as an anti-apoptotic factor, rather than a proliferative signal for Sertoli cells (Meachem et al., 2001; Huhtaniemi, 2015) . The role of FSH in human spermatogenesis has not been fully elucidated. However, in mature rodent models, germ cells are lost through apoptosis when FSH action is neutralized (Meachem et al., 1999) , although pioneering work on the role of FSH in Sertoli cell proliferation has proven differently (Orth, 1986) .
Germ cells do not express receptors for either FSH or androgens, therefore suggesting that the effect on spermatogenesis is mediated through Sertoli cells via production of other hormones acting in a paracrine, autocrine or endocrine fashion. Sertoli cells express the androgen receptor (AR) and it is wellestablished that adequate levels of intratesticular testosterone are required for successful spermatogenesis. As a member of the TGF-b superfamily (Cate et al., 1986) , AMH binds to a heteromeric complex of types I and II single transmembrane serine/threonine kinase receptors (Jamin et al., 2003) . Until recently, only the type 2 receptor, AMHR-II, had been identified. This receptor is expressed on mesenchymal cells surrounding the M€ ullerian ducts and on granulosa cells; AMHR-II is also expressed on Sertoli and Leydig cells, suggesting a more complex interplay between the two cellular populations (Visser, 2003) . The type 1 receptor seem to be shared with other members of the TGF-b superfamily: Three type 1 receptors for bone morphogenetic proteins (BMPs), ALK2, ALK3 and ALK6, are possible candidates (Josso & Di Clemente, 2003; Belville et al., 2005) .
REGULATION OF AMH EXPRESSION
Anti-M€ ullerian hormone (AMH), previously described as M€ ullerian inhibiting substance, is a 140 kD homodimeric disulfide-linked glycoprotein belonging to the TGF-b superfamily (Cate et al., 1986) and secreted in males by Sertoli cells. Expression of AMH is largely dependent on the maturation status of Sertoli cells, as shown by the changes in AMH concentration during fetal life, before puberty and in adults: As expression of androgen receptors increases, AMH production is progressively downregulated (Chemes et al., 2008; Grinspon et al., 2013) . Higher AMH concentrations are therefore expected in early stages of testicular development, as a result of reduced androgen receptor expression in Sertoli cells (Chemes et al., 2008; Grinspon et al., 2013) . In the fetal male gonad, transcription factor SOX9 acts as a trigger for AMH expression, which is then regulated by different transcription factors including SF1 (steroidogenic factor 1), WT1 (Wilms' tumor 1) GATA4, and FSH (Rey et al., 2003) . Evidence from in vitro studies hints at the direct interaction between SOX9 and SF1 as a key point for AMH expression (De Santa Barbara et al., 1998) , but our knowledge of the exact mechanisms involved in AMH regulation is still largely unknown (Miyamoto et al., 2008) . At a later stage of gestation, FSH induces production of AMH by immature Sertoli cells. Following birth, AMH concentrations mirror the delicate balance between the stimulating effects of FSH and the inhibiting effects of testosterone. During infancy and when approaching puberty, Sertoli cells shift their pattern of protein expression and establish tight junctions as a consequence of dramatic changes in both their structure and function: AMH expression is progressively reduced, up to the point of becoming almost undetectable, during transition to adulthood. In puberty, the increasing levels of intra testicular testosterone inhibit AMH secretion, possibly by inducing maturation of Sertoli cells rather than by direct action; however, recent findings suggest a direct effect as well, involving the binding sites for SF1 in the proximal promoter of the AMH gene (Edelsztein et al., 2018) . Precocious puberty is associated with a decline in AMH secretion: In a study involving six male patients with central precocious puberty, a significant decrease in serum AMH was observed in subjects older than 1 year which was then restored to pre-pubertal levels by adequate GnRH analogue treatment (Grinspon et al., 2013) . The maturation process throughout pubertal development is accompanied by morphological changes of Sertoli cells and reflected by distinct changes in histoskeleton architecture identified by immunohistochemical markers (Franke et al., 2004; Schubert et al., 2011; Pleuger et al., 2016) .
In females, AMH is produced by granulosa cells of the preantral and small antral follicles and is therefore detectable in serum only before menopause. Inconsistent findings have emerged from studies investigating the effects of conditions such as vitamin D deficiency, obesity, and smoking on AMH secretion (Shahrokhi et al., 2018) . AMH measurement can be used as an adjunct to other metabolic variables in polycystic ovary syndrome (PCOS) diagnosis (Pellatt et al., 2010) ; although AMH directly correlates with the severity of hyperandrogenism and ovulatory disorders, the lack of a universally accepted threshold and the inter-assay variability both make AMH useful as a surrogate marker, rather than an additional item for the Rotterdam classification (Dewailly et al., 2014) . Effects on the progeny of AMH-treated mice have been recently elucidated, suggesting a possible mechanisms of trans-generational transmission (Tata et al., 2018) .
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AMH IN TESTICULAR PATHOPHYSIOLOGY
The AMH exerts its function on the target tissues by binding to its receptor (AMHR-II), which is expressed on Sertoli and Leydig cells, as well as on the paramesonephric ducts (Matuszczak et al., 2013) . In the early stages of fetal life, the interaction between AMH and its receptor induces a change in the morphology of the M€ ullerian duct mesenchyme, ultimately resulting in apoptosis in the cells of paramesonephric ducts, regression of internal female genitalia, and epitheliomesenchymal transformation (M€ ullerian ducts, uterus, fallopian tubes, and upper vagina) (Allard et al., 2000; Roberts et al., 2002; Roly et al., 2018) . At the same time, testosterone stimulates differentiation of the Wolffian ducts into vas deferens, epididymis, and seminal vesicles. It should be therefore expected that AMH is among the key hormones involved in sex differentiation: Mutations in either AMH or AMHR-II result in a rare condition defined persistent M€ ullerian duct syndrome (PMDS), in which derivatives of M€ ullerian ducts are seen in phenotypically normal 46,XY male subjects. This condition is the result of masculinizing effects from endogenous testosterone, which affects Wolffian ducts, and absent pro-apoptotic effects on the M€ ullerian ducts.
Once Sertoli cells reach their maturation serum concentrations of AMH undergo a rapid decline; however, AMH is preferentially released in the seminiferous tubules, where it reaches far greater concentrations than in the serum (Matuszczak et al., 2013) . In newborns, measurement of AMH might be helpful in discerning bilateral cryptorchidism from anorchia. In fact, as Sertoli and granulosa cells are the only source of AMH, pre-pubertal females should have undetectable AMH levels; therefore, measurable concentrations of AMH are strongly suggestive of the presence of testicular tissue. Likewise, serum AMH is a valid and reliable tool for differential diagnosis between congenital hypogonadotropic hypogonadism and constitutional delay in growth and puberty (Condorelli et al., 2018) . In the pre-pubertal testis, Sertoli cells are the most prevalent and the most active cell population (Edelsztein et al., 2016) , and as such markers of their development are more reliable than those associated with Leydig cell function (Rohayem et al., 2015b) . Subjects with delayed puberty show normal AMH levels for their age, while patients with congenital hypogonadotropic hypogonadism have markedly reduced AMH as a result of impaired development of Sertoli cells (Adan et al., 2010) .
In Klinefelter patients, normal levels of serum AMH, inhibin B, and FSH are observed until late puberty (Bastida et al., 2007; Aksglaede et al., 2011) , with a subsequent decline possibly from hyalinization of seminiferous tubules. In these subjects, chances of sperm retrieval via mTESE (microdissection testicular sperm extraction) are largely dependent on spermatogenetic maturity -therefore suggesting that markers of Leydig cell development, as well as age, should be considered more reliable predictors than AMH and Inhibin B (Rohayem et al., 2015a) .
Exogenous FSH administration, as currently used in the treatment of infertile males, is associated with an increase in serum AMH (Young et al., 2005; Colacurci et al., 2018) , possibly as a result of enhanced gonadal function. However, hCG administration inhibits AMH secretion from Sertoli cells, whether alone or in combination with FSH (Young et al., 2005; Sinisi et al., 2008) . This effect is possibly the result of the increased intra testicular concentration of testosterone due to hCG and fits nicely with evidence suggesting that priming with FSH improves testicular function (Raivio et al., 2007; Isidori et al., 2017; Rohayem & Nieschlag, 2017) .
Serum AMH is positively correlated with testicular volume and negatively correlated with serum FSH, but only in men with history of testicular maldescent (T€ uttelmann et al., 2009) , possibly proving the presence of persisting damage and functional de-differentiation of Sertoli cells (Sharpe et al., 2003) . Several reports suggest lower levels of AMH in children with bilateral or unilateral cryptorchidism (Condorelli et al., 2018; Grinspon et al., 2018) , providing further confirmation of this theory; similarly, testicular dysgenesis syndrome has been associated with disruption in Sertoli cell maturation, a phenomenon which might contribute to the functional impairment of the Sertoli cell and therefore to reduced AMH secretion (Nistal et al., 2013) .
Few studies have assessed the relationship between varicocele and AMH. A single study (Trigo et al., 2004) found increased serum AMH levels in adolescent males with varicocele compared to healthy controls, whereas another study on adult men found no significant difference compared to controls in regard to serum AMH, but found lower concentration of AMH in the spermatic veins of varicocele patients (Goulis et al., 2011) . While more solid evidence concerning decreased inhibin B in patients with varicocele suggests a negative effect on Sertoli cell development, the paucity of studies on the association between AMH and varicocele does not allow drawing conclusions in these regards.
Modifications of Sertoli cell structure and patterns of protein expression in most forms of cancer also provide an explanation in regard to the changes in serum AMH detectable in patients with testicular tumors (Rey et al., 2000; Edelsztein et al., 2016) . So far, however, the role of AMH as a testicular tumor marker is debated: In females, AMH is most commonly recognized as a marker for granulosa cell tumors of the ovary (Rey et al., 1996; F€ arkkil€ a et al., 2015) , whereas reports concerning its validity in the diagnosis of Sertoli cell tumors mostly come from animal models (Holst & Dreimanis, 2015; Claes & Ball, 2016) . New findings also suggest a possible role for serum AMH and the ratio of AMH to total testosterone as independent predictor biomarkers for successful sperm retrieval at microTESE (Alfano et al., 2017) .
REGULATION OF INSL3 EXPRESSION
INSL3 is a 'neohormone'-that is, an adaptation of the endocrine system, stemming from the increasingly complex regulations of reproduction resulting from evolution (Anand- Ivell et al., 2013) . Production of INSL3 occurs exclusively in mammalian Leydig cells: In fact, INSL3 is undetectable in anorchid men (Foresta et al., 2004; Bay & Andersson, 2011) . INSL3 is constitutively secreted by Leydig cells without direct acute regulation by the HPG axis, therefore being a marker of Leydig cell function and differentiation status (Ivell et al., 2014) . It is therefore unsurprising that INSL3 expression closely mirrors the patterns of Leydig cell activity and population size, with a transient increase during fetal life, a second peak occurring roughly 3 months after birth ('mini-puberty'), and a third increase during puberty (Ferlin et al., 2006) , which ultimately leads to persisting high concentrations during adult life (Bay & Andersson, 2011 ) with a slight reduction in older age (Anand-Ivell et al., 2006) . Although acute regulation of the HPG axis is not involved in INSL3 expression, it should be noted that LH stimulation is needed for Leydig cells differentiation and measurable levels of INSL3 after pubertal development: Further proof of this comes from treatment of congenital hypogonadotropic hypogonadism, as men undergoing testosterone treatment show undetectable INSL3 levels whereas a significant increase in INSL3 is observed in patients treated with hCG (Bay et al., 2005) phases of testicular descent likely require both INSL3/RXFP2 and testosterone/AR interaction (Yuan et al., 2010) . Mutations in the INSL3 or RXFP2 genes are associated with cryptorchidism, but they only account for a small percentage of cases: Frequency of these mutations is 1.8% and 2.9% for INSL3 and RXFP2, respectively, but clinical phenotypes vary, and spontaneous descent during the first years of life has also been reported .
INSL3 has proven useful as a surrogate marker of endocrine disruption. Studies in rodent models have proven downregulation of Insl3 gene expression in the fetal testis following administration of diethylstilbestrol (DES) to pregnant mice (Emmen et al., 2000) . This finding corroborates the clinical finding that associated cryptorchidism with administration of DES to pregnant mothers ('blacklisted' by the FDA in the early 1970s, but widely used before that).
BEYOND REPRODUCTION: EXTRA GONADAL PATHOPHYSIOLOGY OF AMH AND INSL3
AMH has been largely considered in recent times as a valid marker for ovarian reserve (van Rooij et al., 2002) , whereas no function has been attributed to it in adult males despite detectable serum levels. Some reports have suggested a possible role for AMH in cardiovascular prevention in elderly men Dennis et al., 2013) , as well as in Klinefelter pre-pubertal boys (Davis et al., 2016) and in premenopausal women (Appt et al., 2012) : in fact, AMH inversely correlated with the ultrasonographic diameters of the distaland mid-infrarenal aorta, independently of other markers of Sertoli cell function such as inhibin B . These results require further confirmation, but are plausible given that AMH has been identified as a potent regulator of TGF-b/BMP signaling (Beck et al., 2016) , which is in turn involved in vascular development (Lowery & de Caestecker, 2010; Cai et al., 2012) .
The most known function of INSL3, as previously stated, involves testicular descent. However, the expression of INSL3 occurs throughout all adult life-therefore suggesting that INSL3 might actually be involved in other conditions. Further proof of an endocrine role for INSL comes from identification of RXFP2 in several other organs, including thyroid, seminal vesicles, kidney, brain, and bone marrow.
It has been hypothesized that some of the defining features of male hypogonadism might actually be the result of reduced INSL3 levels, or at least that low INSL3 might contribute to signs and symptoms of male hypogonadism, such as muscle wasting (Ferlin et al., 2017 . Impaired bone mineral density was the first clinical finding described in association with inactivating mutations in the humans . This hypothesis seemed valid, considering the common origin of both testosterone and INSL3-the Leydig cell-and the identification of RXFP2 on osteoblasts: Following studies confirmed a role for INSL3 in bone remodeling, as receptor activation stimulates osteoblast proliferation and bone anabolic activity while at the same time influencing osteoclastogenesis (Ferlin et al., 2017) . Furthermore, lower levels of INSL3 have been described in Klinefelter patients compared to healthy controls (Overvad et al., 2014; Di Nisio et al., 2018) and negatively correlated with sclerostin, an osteocyte-specific protein with anti-anabolic effects on bone formation.
CONCLUSIONS
It is currently clear that Leydig and Sertoli cells are able to influence the endocrine milieu of the testes by several pathways ( Fig. 1) and also affecting exocrine testicular function. In these regards, functions of AMH and INSL3 are only beginning to emerge. It is accepted that both hormones are involved in sexual differentiation: Mutations of AMH or its receptor lead to persistence of the M€ ullerian duct, whereas a decrease in INSL3 levels accounts for a small, but relevant, percentage of cases of cryptorchidism. So far, INSL3 and AMH have prevalently been considered for differential diagnosis as reliable markers of maturation of Leydig and Sertoli cells (Table 1 ). The role of both INSL3 and AMH in several conditions, such as varicocele, has only marginally been hinted at. Furthermore, effects of AMH and INSL3 extend beyond gonadal range: Symptoms of male hypogonadism have been often associated with decline in serum INSL3 levels, and reduced AMH concentrations have been correlated with worse cardiovascular conditions.
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